Oncology Intelligence
Unlocking the Power of Oncology Intelligence
to Transform Cancer Research & Diagnostics
Our Oncology Intelligence translates complex tissue patterns into actionable insights, providing a deeper understanding of disease mechanisms and tumor microenvironments, driving biomarker discovery to support drug development and advance precision medicine.
A transformative SaaS enterprise solution utilizing AI to advance translational research and drive progress in drug development and clinical trials.
At its core is our state-of-the-art Oncology Intelligence Foundation Model – a scalable, generalizable, and versatile backbone for diverse oncology applications, from diagnosis to drug biomarker strategies.
“We have reached another significant milestone in digital pathology with this ability to detect biomarkers by AI. The use of deep learning algorithms is changing the world of diagnosis, and in certain cases can drastically shorten the cost and time to treatment. I am excited about the growing number of patients who were able to receive rapid diagnoses and treatment.”
Professor Iris BarshackHead of the Pathology Institute, Sheba Medical Center 
“Tempus is committed to broadly offering AI-enabled diagnostics in an effort to improve patient outcomes. This collaboration with Imagene strengthens our diagnostic offerings and allows us to provide clinicians more actionable data that may lead to additional testing.”
Chris Scotto DiVettaSenior Vice President of AI Products at Tempus
“CanvOI transforms our approach to healthcare and disease understanding. By providing access to comprehensive oncology intelligence in the cloud, it enables researchers to develop answers quicker and more efficiently. This technology marks a new era of cancer research that pushes us closer to a future where cancer is a manageable condition.”
Dr. David AgusFounding Director and Co-CEO, Ellison Medical Institute
“Oncologists already use clinical features like race and smoking status to manage decision-making when treatment delays pending molecular results are likely to be appropriate. I would definitely use a science-forward, reliable, and ultra-rapid AI test to enhance this process in supporting an informed clinical decision.”
Dr. Ross CamidgeProfessor of Medicine, Director of Thoracic Oncology, University of Colorado
"Imagene's AI-based biomarker detection shows great promise for significantly reducing the waiting time for patients to begin targeted therapies. This kind of technology can lead to better
and earlier cancer care for patients no matter where they live.”
Dr. David R. BraxtonChief of Molecular Pathology Services at Hoag
“Unfortunately, we are so used to waiting a long time for molecular cancer testing while patients deteriorate, that such a breakthrough technology, enabling treatment initiation within a day is exceptional. This is a real revolution; this technology is the future for oncology.”
Professor Ido WolfDirector of Oncology, Sourasky Medical Center
“Saving lives is technology's single most important use. We are proud that Oracle’s highly performant and secure cloud infrastructure will help Imagene improve access to care, drive informed decisions, lower costs, and ultimately save lives.”
Safra CatzCEO, Oracle
"The ability to use Imagene's AI technology under research is a game-changer. It allowed us to bypass the usual lengthy waiting period associated with comprehensive genomic profiling. This technology is revolutionizing the way we diagnose patients, with the potential to improve outcomes and save lives."
Professor Dov HershkovitzHead of Pathology, Sourasky Medical Center
“We have reached another significant milestone in digital pathology with this ability to detect biomarkers by AI. The use of deep learning algorithms is changing the world of diagnosis, and in certain cases can drastically shorten the cost and time to treatment. I am excited about the growing number of patients who were able to receive rapid diagnoses and treatment.”
Professor Iris BarshackHead of the Pathology Institute, Sheba Medical Center
“Tempus is committed to broadly offering AI-enabled diagnostics in an effort to improve patient outcomes. This collaboration with Imagene strengthens our diagnostic offerings and allows us to provide clinicians more actionable data that may lead to additional testing.”
Chris Scotto DiVettaSenior Vice President of AI Products at Tempus
“We have reached another significant milestone in digital pathology with this ability to detect biomarkers by AI. The use of deep learning algorithms is changing the world of diagnosis, and in certain cases can drastically shorten the cost and time to treatment. I am excited to hear about the growing number of patients who were able to receive rapid diagnoses and treatment.”
Professor Iris BarshackHead of the Pathology Institute, Sheba Medical Center
“CanvOI transforms our approach to healthcare and disease understanding. By providing access to comprehensive oncology intelligence in the cloud, it enables researchers to develop answers quicker and more efficiently. This technology marks a new era of cancer research that pushes us closer to a future where cancer is a manageable condition.”
Dr. David AgusFounding Director and Co-CEO, Ellison Medical Institute
“Tempus is committed to broadly offering AI-enabled diagnostics in an effort to improve patient outcomes. This collaboration with Imagene strengthens our diagnostic offerings and allows us to provide clinicians more actionable data that may lead to additional testing.”
Chris Scotto DiVettaSenior Vice President of AI Products at Tempus
“Saving lives is technology's single most important use. We are proud that Oracle’s highly performant and secure cloud infrastructure will help Imagene improve access to care, drive informed decisions, lower costs, and ultimately save lives.”
Safra CatzCEO, Oracle
"Imagene's AI-based biomarker detection shows great promise for significantly reducing the waiting time for patients to begin targeted therapies. This kind of technology can lead to better
and earlier cancer care for patients no matter where they live.”
Dr. David R. BraxtonChief of Molecular Pathology Services at Hoag
“Oncologists already use clinical features like race and smoking status to manage decision-making when treatment delays pending molecular results are likely to be appropriate. I would definitely use a science-forward, reliable, and ultra-rapid AI test to enhance this process in supporting an informed clinical decision.”
Dr. Ross CamidgeProfessor of Medicine, Director of Thoracic Oncology, University of Colorado
“Unfortunately, we are so used to waiting a long time for molecular cancer testing while patients deteriorate, that such a breakthrough technology, enabling treatment initiation within a day is exceptional. This is a real revolution; this technology is the future for oncology.”
Professor Ido WolfDirector of Oncology, Sourasky Medical Center
"The ability to use Imagene's AI technology under research is a game-changer. It allowed us to bypass the usual lengthy waiting period associated with comprehensive genomic profiling. This technology is revolutionizing the way we diagnose patients, with the potential to improve outcomes and save lives."
Professor Dov HershkovitzHead of Pathology, Sourasky Medical Center
“We have reached another significant milestone in digital pathology with this ability to detect biomarkers by AI. The use of deep learning algorithms is changing the world of diagnosis, and in certain cases can drastically shorten the cost and time to treatment. I am excited to hear about the growing number of patients who were able to receive rapid diagnoses and treatment.”
Professor Iris BarshackHead of the Pathology Institute, Sheba Medical Center
“CanvOI transforms our approach to healthcare and disease understanding. By providing access to comprehensive oncology intelligence in the cloud, it enables researchers to develop answers quicker and more efficiently. This technology marks a new era of cancer research that pushes us closer to a future where cancer is a manageable condition.”
Dr. David AgusFounding Director and Co-CEO, Ellison Medical Institute
Our Medical Advisory Board
World-Leading Experts at the Forefront of Healthcare & Precision Oncology
Dept. of Clinical Oncology
Chinese University, Hong Kong
Tony Mok, MD. 
Founding CEO Ellison Medical Institute
David Agus, MD. 
Princess Margaret Cancer Centre, University of Toronto
Natasha Leighl, MD. 
The Ohio State University Comprehensive Cancer Center
Christian Rolfo, MD., PhD. 
University of Colorado Cancer Center, Aurora, Colorado
Ross Camidge, MD., PhD. 
Dept. of Clinical Oncology
Chinese University, Hong Kong
Tony Mok, MD.
Founding CEO Ellison Medical Institute
David Agus, MD.
David Agus, MD.
Founding CEO
Ellison Medical Institute
Natasha Leighl, MD.
Princess Margaret Cancer Centre, University of Toronto
Christian Rolfo, MD., PhD.
The Ohio State University Comprehensive Cancer Center
Ross Camidge, MD., PhD. University of Colorado Cancer Center, Aurora, Colorado
Tony Mok, MD.
Dept. of Clinical Oncology
Chinese University, Hong Kong